Top Stories
FDA Flags Foundayo for “Serious” Cardiovascular and Liver Safety Signals, Demands Postmarketing Clinical Trial
The FDA disclosed in its April 1 approval letter that Foundayo (orforglipron) triggered safety signals serious enough to require a full clinical trial—not merely an observational study—to assess risks of major adverse cardiovascular events (MACE), drug-induced liver injury (DILI), and retained gastric contents. The agency gave Lilly a July deadline to submit cardiovascular and liver data from the ongoing Phase 3 ACHIEVE-4 trial. The disclosure carries immediate competitive implications: Foundayo was approved under the FDA Commissioner's National Priority Voucher Program just 50 days after filing, raising questions about whether the accelerated timeline traded review thoroughness for speed. Novo will almost certainly weaponize these safety flags in physician and payer conversations, positioning oral Wegovy's longer-established semaglutide safety database as the lower-risk oral option. Novo Nordisk, which gains a safety-narrative advantage in oral GLP-1 positioning despite Foundayo's convenience edge Lilly, facing postmarketing obligations that could slow formulary placement if safety data shows any signal persistence BMO Capital Markets noted the FDA requirements are standard for accelerated approvals, but the explicit use of the word “serious” in connection with MACE and DILI is atypical for a GLP-1 class drug and will require proactive management by Lilly's medical affairs team.
Lilly Fires Back: ACHIEVE-4 Shows 16% MACE Reduction, 57% Lower All-Cause Death, and Zero DILI Signals
Lilly moved to neutralize the FDA safety narrative within days, releasing ACHIEVE-4 results from 2,700 patients with type 2 diabetes and obesity at elevated cardiovascular risk. Foundayo demonstrated non-inferiority to insulin glargine on MACE, with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events. The headline figure was a 57% reduction in all-cause mortality versus insulin glargine—a number Leerink Partners called “outstanding” that positions Foundayo for a rapid diabetes filing. Crucially, zero drug-induced liver injury signals were observed, directly addressing the FDA's primary safety concern. Lilly plans to submit Foundayo for a T2D indication via the same Commissioner's National Priority Voucher program by end of Q2 2026. The treatment discontinuation rate was 10.6% in year one, mainly from GI side effects consistent with the GLP-1 class. Lilly, which now holds 104-week safety data across seven Phase 3 studies enrolling 11,000+ patients, materially de-risking the Foundayo franchise Novo's safety-narrative window closes rapidly as ACHIEVE-4 data circulates to physicians and payers Leerink now expects a diabetes approval in H2 2026, ahead of prior consensus for 2027.
Obesity Dealmaking Hits $22B in Q1 2026, Already Surpassing Full-Year 2025 Total
J.P. Morgan's Q1 licensing and venture report revealed that obesity and diabetes deal commitments reached $22 B through March 31—exceeding the full 2025 total of $20.3 B in just three months. Upfront cash and equity commitments hit $1.3 billion, nearly half of 2025's $2.9 billion full-year total. The quarter was anchored by AstraZeneca's $1.2 billion upfront deal with CSPC Pharmaceutical for a long-acting dual GLP-1/GIP asset (total deal value: $17 billion+), Pfizer's $495 million deal with Sciwind Biosciences for a China-approved GLP-1 injection, and Lilly's $55 million Nimbus Therapeutics collaboration on a preclinical weight-loss asset. Notably, J.P. Morgan flagged a structural shift: pure GLP-1/GIP deals slowed to just two transactions in Q1 versus 12 in peak year 2023, while total metabolic deal flow is concentrating into fewer, higher-value transactions. AstraZeneca, which secured the quarter's largest deal and is building a late-stage metabolic pipeline from scratch via licensing Mid-tier biotechs with undifferentiated GLP-1 assets, as deal flow concentrates in high-value platforms and novel mechanisms
Pipeline Watch
With ACHIEVE-4 data in hand, Lilly confirmed plans to file Foundayo for type 2 diabetes by end of Q2 2026, using the same CNPV program that delivered the obesity approval in 50 days. If the diabetes review follows a similar timeline, Foundayo could have a T2D label by late summer—leapfrogging oral Wegovy's Rybelsus franchise, which launched for diabetes in 2019 but has plateaued at roughly $2.7 billion annually. Leerink Partners now expects FDA approval in H2 2026, ahead of prior consensus for 2027.
IQVIA data shows Foundayo generated 1,390 prescriptions in its first week (based on two days of capture ending April 10), a solid start but roughly half of oral Wegovy's 3,071 prescriptions during its first four days in January. UBS analysts project Lilly needs 5.4–6 million prescriptions from April through December to hit consensus 2026 revenue estimates of $1.7–$2 billion. Analysts at Jefferies see the launch building momentum as Medicare Part D coverage expands July 1.
Beyond the headline cardiovascular and liver concerns, the FDA approval letter requires Lilly to establish a registry tracking outcomes in pregnant women and children taking Foundayo for obesity, and to conduct ongoing monitoring for thyroid C-cell tumors—a class-wide GLP-1 concern. These postmarketing commitments add long-term pharmacovigilance costs but are consistent with the broader GLP-1 regulatory framework. Analysts view these requirements as manageable rather than franchise-threatening.
Novo Nordisk's semaglutide NASH study (NCT04822181) has transitioned to active-not-recruiting status, signaling imminent Phase 3 data readout. Phase 2 ESSENCE data showed 59% NASH resolution versus 17% placebo. A positive readout would give Novo first-mover MASH label advantage 12–18 months ahead of Lilly's SYNERGY-NASH tirzepatide trial, which is still enrolling. The MASH market is projected at $18–24 billion by 2030.
Lilly is recruiting for a combination trial pairing tirzepatide with mirikizumab (IL-23 inhibitor) in adults with moderately to severely active Crohn's disease who also carry obesity. Roughly 30–40% of Crohn's patients are obese, and obesity drives worse disease outcomes. This cross-franchise play creates a clinical narrative Novo cannot replicate without an equivalent immunology asset, potentially justifying premium bundle pricing across Lilly's metabolic and immunology portfolios.
Competitive Landscape
The FDA's “serious” safety language on April 15 and Lilly's ACHIEVE-4 response on April 16 compressed a full safety controversy cycle into two days. Lilly, which had ACHIEVE-4 data ready to deploy immediately, limiting the window for Novo to exploit the safety narrative Novo, whose brief safety-narrative advantage evaporated before it could be operationalized in formulary or physician messaging The execution lesson: Foundayo was approved under CNPV before ACHIEVE-4 data was released, a sequencing risk Lilly managed by having the data locked and ready.
| Metric | Foundayo (ACHIEVE-4) | Oral Wegovy (OASIS 4) |
|---|---|---|
| CV Safety Data | MACE-4 reduction 16% | SELECT: 20% MACE reduction (injectable) |
| All-Cause Death | 57% reduction vs insulin | Not reported (oral) |
| DILI Signals | Zero | Not a flagged concern |
| Trial Size | 2,700 patients | 667 patients (OASIS 4) |
J.P. Morgan's Q1 data reveals a structural shift: pure GLP-1/GIP deals dropped from 12 (2023) to 8 (2025) to just 2 in Q1 2026, even as total metabolic deal value hit a record $22 billion. Capital is migrating toward differentiated mechanisms (amylin, dual/triple agonists, long-acting depots) and platform acquisitions. Companies with novel mechanism assets (amylin, oral small molecules, monthly depots) command premium valuations Undifferentiated weekly GLP-1 RA developers face a closing window for partnerships as strategic buyers consolidate around fewer, larger bets
| Quarter | Total Metabolic Deal Value | GLP-1/GIP Deals | Upfront Cash |
|---|---|---|---|
| 2023 Full Year | $9.6B | 12 | N/A |
| 2025 Full Year | $20.3B | 8 | $2.9B |
| Q1 2026 Only | $22B | 2 | $1.3B |
Oral Wegovy hit 3,000+ scripts in its first four days and continues to climb. Foundayo opened at ~1,390 in two capture days. Analysts project the gap will narrow as Foundayo's no-fasting-required convenience resonates and Medicare Part D coverage launches July 1. RBC estimates peak Foundayo US sales of $36 billion. The overall oral GLP-1 market, which is expanding the patient base: 36% of early oral Wegovy patients were GLP-1 naive Injectable GLP-1 franchise revenues, as cannibalization from oral options accelerates through H2 2026
Forward Looking
- Lilly's July deadline to submit ACHIEVE-4 cardiovascular and liver safety data to the FDA is the next critical regulatory milestone. A clean submission closes the postmarketing safety chapter; any signal persistence would re-open the narrative.
- Watch for Lilly's T2D filing for Foundayo via the Commissioner's National Priority Voucher program by end of Q2 2026. If review speed matches the obesity filing, a diabetes approval could arrive by late summer—accelerating the Foundayo franchise beyond single-indication risk.
- Novo reports Q1 2026 earnings in May, the first quarter to include oral Wegovy revenue. These results will set the baseline for the oral GLP-1 market and provide the first hard data on injectable-to-oral cannibalization rates within the Wegovy franchise.
- Medicare Part D GLP-1 coverage expands July 1 with co-pays as low as $50/month. Monitor formulary tier placement decisions for Foundayo vs. oral Wegovy at the top five Part D plans—safety narrative positioning from this week may influence initial tier assignments.
- Track whether AstraZeneca's $17 billion CSPC deal and Pfizer's Metsera integration generate Phase 3 readiness updates in Q2–Q3. These late entrants will define whether the 2027–2028 competitive field expands beyond the Novo-Lilly duopoly or remains a two-player market.